Age
(≥65 years)
Age
(≥65 years)
We encountered an unexpected error, we encourage you to try again later.
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.
To gain access please enter your professional information within your account.
Should you need further support updating your account information, please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
All samples available online to you are included below. Availability is updated periodically.
Savings cards will be shipped with Product Samples, if applicable.
Use your mouse, finger, or stylus to sign below.
I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.
We have received your order and are getting it ready
Download available co-pay cards and patient savings offers across select Pfizer products.
Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.
Changes you have made will not be saved.
This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
130,000-240,000
COVID-19–associated hospitalizations§
130,000-240,000
COVID-19–associated
hospitalizations§
14,000-41,000
COVID-19–associated deaths
14,000-41,000
COVID-19–associated deaths
130,000-240,000
COVID-19–associated hospitalizations§
14,000-41,000
COVID-19–associated deaths
Adults ≥65 years or 18-64 years with 1 or more UMC are at an increased risk of severe outcomes from COVID-19.2 See a list of UMCs from cdc.gov
The CDC defines severe outcomes of COVID-19 as hospitalization, admission to the intensive care unit (ICU), intubation or mechanical ventilation, or death.2
Some emergency warning signs|| for COVID-19 are5:
If someone is showing any of these signs, call 911 or call ahead to your local emergency facility. Notify the operator that you are seeking care for someone who has or may have COVID-19.
For more information on signs and symptoms of COVID-19, visit cdc.gov
Asthma/chronic lung conditions
Asthma/chronic lung conditions
Coronary artery disease
Coronary artery disease
Coronary artery disease
Medical associations, such as AAFP, AMA, and IDSA, in addition to the CDC, recommend vaccination for adults aged ≥65 years and adults with UMCs who are at high risk for severe outcomes from COVID-19, guided by shared clinical decision-making.7-10
From September 5, 2025, to April 3, 2026, few eligible adults received a 2025-2026 formula COVID-19 vaccine11*:
of eligible adults ≥18 years with a UMC received a COVID-19 vaccination
of eligible adults ≥18 years with a UMC received a COVID-19 vaccination
Talk to patients about how their risk factors, like age and UMCs, can put them at high risk for severe outcomes from COVID-19, and the importance of taking steps to help protect themselves.2,12
Talk to patients about how their risk factors, like age and UMCs, can put them at high risk for severe outcomes from COVID-19, and the importance of taking steps to help protect themselves.2,12
Identifying high-risk individuals2
For your patients ≥65 years or those 18-64 years with 1 or more UMC, consider explaining why they are at high risk for severe outcomes from COVID-192†
Recommending vaccination12
• Consider discussing preventative vaccination options
• Consider taking steps to help encourage follow-through
Manufactured for
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany
Marketing Authorization Holder
Manufactured by
Pfizer Inc.
New York, NY 10001
The formulation of COMIRNATY, which is based on BioNTech proprietary mRNA technology, was developed by BioNTech and Pfizer.
The formulation of COMIRNATY, which is based on BioNTech proprietary mRNA technology, was developed by BioNTech and Pfizer.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2026 Pfizer Inc. All rights reserved.
You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Myocarditis and Pericarditis
Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.